文献速递消化道肿瘤放疗

接触X线近距离治疗作为早期直肠癌选定患者的单一治疗——多中心研究

Contact X-ray Brachytherapy as a sole treatment in selected patients with early rectal cancer - Multi-centre study.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-09-06

这项回顾性多中心研究(2009—2021年)评估了76例T1/2-N0-M0直肠腺癌患者单纯接受接触X线近距离治疗(CXB)的疗效。中位随访26个月,初始临床完全缓解率为82%,3年局部控制率84%,5年无病生存率和总生存率分别为66%和58%。结论认为CXB单药治疗可获得较高的临床完全缓解率及令人满意的局部控制和DFS,肿瘤学结局在既往接受过盆腔放疗的患者中较差。

要点

  • 76例T1/2-N0-M0直肠腺癌患者单纯CXB治疗,中位随访26个月,初始临床完全缓解率82%。
  • 3年局部控制率84%,局部再生率18%,远处复发率3%,无淋巴结复发。
  • 5年无病生存率66%,总生存率58%;B组和C组总生存较差(HR分别为2.54和2.75)。

核心结论

  • CXB单药治疗可获得较高的临床完全缓解率及令人满意的局部控制和DFS。
  • 既往接受过盆腔放疗的患者肿瘤学结局较差。
  • CXB单药治疗毒性良好并可避免全身麻醉和手术风险,因此可考虑用于不适合或拒绝手术的患者。

研究设计与样本

  • 回顾性多中心研究,纳入2009—2021年间76例接受单纯CXB治疗的T1/2-N0-M0直肠腺癌患者。
  • 按T分期及接受单纯CXB的标准分为三组:A组为适合手术但拒绝者,B组为手术高风险者,C组为既往因其他癌症接受过盆腔放疗者。
  • 对全部队列及亚组评估结局。

主要发现

  • 中位随访26个月(IQR:12-49),初始临床完全缓解率为82%(70-93%)。
  • 局部再生率为18%(8-29%),3年实际局部控制率为84%(75-95%),远处复发率3%,无淋巴结复发。
  • 5年无病生存率为66%(48-78%),总生存率为58%(44-75%)。
  • B组总生存较低(HR 2.54,95%CI 1.17-5.59,p=0.02),C组总生存较低(HR 2.75,95%CI 1.15-6.58,p=0.03)。
  • 既往盆腔放疗预测较低的临床完全缓解率和总生存;主要毒性为G1-2直肠出血(26%),未报告肛门括约肌功能受损症状。

临床怎么用

  • 作者认为,CXB单药治疗毒性良好并可避免全身麻醉和手术风险,可考虑用于不适合或拒绝手术的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radical surgery is the standard of care for early rectal cancer. However, alternative organ-preserving approaches are attractive, especially in frail or elderly patients as these avoid surgical complications. We have assessed the efficacy of sole Contact X-ray Brachytherapy (CXB) treatment in stage-1 rectal cancer patients who were unsuitable for or declined surgery. MATERIALS AND METHODS: This retrospective multi-centre study (2009-2021) evaluated 76 patients with T1/2-N0-M0 rectal adenocarcinomas who were treated with CXB alone. Outcomes were assessed for the entire cohort and sub-groups based on the T-stage and the criteria for receiving CXB alone; Group A: patients who were fit enough for surgery but declined, Group B: patients who were high-risk for surgery and Group C: patients who had received prior pelvic radiation for a different cancer. RESULTS: With a median follow-up of 26(IQR:12-49) months, initial clinical Complete Response (cCR) was 82(70-93)% with rates of local regrowth 18(8-29)%, 3-year actuarial local control (LC) 84(75-95)%, distant relapse 3 %, and no nodal relapse. 5-year disease-free survival (DFS) and overall survival (OS) were 66(48-78)% and 58(44-75)%. Lower OS was observed in Groups B [HR:2.54(95 %CI:1.17, 5.59), p = 0.02] and C [HR:2.75(95 %CI:1.15, 6.58), p = 0.03]. Previous pelvic radiation predicted lower cCR and OS. The main toxicity was G1-2 rectal bleeding (26 %) and symptoms of impaired anal sphincter function were not reported in any patients. CONCLUSION: CXB treatment alone achieved a high cCR rate with satisfactory LC and DFS. Inferior oncological outcomes were observed in patients who had received prior pelvic radiotherapy. CXB alone, with its favourable toxicity profile and avoidance of general anaesthesia and surgery risks, therefore, can be considered for patients who are unsuitable for or refuse surgery.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wah Than N, Mark Pritchard D, Hughes DM, et al. Contact X-ray Brachytherapy as a sole treatment in selected patients with early rectal cancer - Multi-centre study. Clin Transl Radiat Oncol. 2024. PMID: 39308635. doi:10.1016/j.ctro.2024.100851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。